RNS & Investor News

Consumer Survey of GoFigure® products

06 September 2016

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the results of an independent consumer survey of the GoFigure® products. These products, in the form of meal replacement shakes and natural snack bars, contain SlimBiome®. This is OptiBiotix's patented formulation developed by experts in nutrition using ingredients shown to reduce weight in human studies. GoFigure® products are produced by OptiBiotix's majority owned subsidiary, The Healthy Weight Loss Company.

The results of the survey showed:-

  1. 100% of customers who used the products over a continued period lost weight (average 1.2kg weight loss per week, based on average reduction of 7-9 lbs over three weeks)
  2. 100% of customers reported that using GoFigure® products led them to reduce food intake (typically by eating smaller food portions)
  3. 93% of customers reported that using GoFigure products had led to reduced snacking
  4. 83% of customers reported they felt less hungry when using the product

This consumer survey was carried out by contacting customers who bought directly from the GoFigure website with a response rate of 24% (30 customers).

Stephen O'Hara, CEO of OptiBiotix, commented: "We are delighted that this customer survey supports the science behind the SlimBiome formulation with GoFigure® customers reporting reduced hunger, less snacking and easier weight loss. This new approach to weight loss contrasts with many competitor products which lack strong scientific rationale and typically rely on customers' self-control to restrict calories and as a consequence have a high failure rate. These results show that the incorporation of SlimBiome® into food products helps customers to manage their weight loss by reducing food intake without food cravings. Hunger free dieting is now a consumer option and we hope to see a wider range of products containing this unique formulation to support consumer choice."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.


For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd (Joint Broker)
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002


About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.